The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,001–2,100 of 4,628
Kobayashi, K., Suzukawa, M., Watanabe, K., Arakawa, S., Igarashi, S., Asari, I., Hebisawa, A., Matsui, H., Nagai, H., Nagase, T., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13390 · Cited by 19
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 17
Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management
Pérez, E. R. F., Koelsch, T. L., Leone, P. M., Groshong, S. D., Lynch, D. A., & Brown, K. K. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1701250 · Cited by 17
Self-citationSchmid, U., Weber, B., Magnusson, M. O., & Freiwald, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106369 · Cited by 15
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis
Sgalla, G., Comes, A., & Richeldi, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1921143 · Cited by 18
Self-citationLi, G., Zhang, Y., Jiang, H., Wu, X., Hao, Y., Su, Y., Zou, Y., Xian, W., Wang, F., & Du, Q. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41628 · Cited by 23
Impact of Pulmonary Rehabilitation on Survival in People With Interstitial Lung Disease
Dowman, L., Vainshelboim, B., & Holland, A. E. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.01.001 · Cited by 16
Feng, Y., Su, Q., Zhu, J., Cui, X., Guo, J., Yang, J., & Zhang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114144 · Cited by 16
Li, R. M., Tan, D. B. A., Tedja, C., Cooper, W. A., Jo, H. E., Grainge, C., Glaspole, I., Goh, N. S. L., Ellis, S. J., Hopkins, P. M.-A., et al. (2025) · Respirology · doi:10.1111/resp.14894 · Cited by 16
Qiu, Y., & Ye, W. (2025) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_132_25 · Cited by 16
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 21
Under‐recognised co‐morbidities in idiopathic pulmonary fibrosis: A review
de Boer, K., & Lee, J. S. (2015) · Respirology · doi:10.1111/resp.12622 · Cited by 15
Inoue, Y., Suda, T., Kitamura, H., Okamoto, M., Azuma, A., Inase, N., Kuwana, M., Makino, S., Nishioka, Y., Ogura, T., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106574 · Cited by 16
Self-citationWang, H., Yang, R., Jin, J., Wang, Z., & Li, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259784 · Cited by 16
[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
RetractedUrushiyama, H., Jo, T., Hasegawa, W., Yokoyama, A., Ando, T., Sakamoto, Y., Kumazawa, R., Uda, K., Michihata, N., Awano, N., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00209-2022 · Cited by 17
Fan, G., Liu, J., Wu, Z. S., Li, C., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049361 · Cited by 26
Fujii, H., Hara, Y., Saigusa, Y., Tagami, Y., Murohashi, K., Nagasawa, R., Aoki, A., Izawa, A., Seki, K., Watanabe, K., et al. (2023) · Canadian Respiratory Journal · doi:10.1155/2023/5088207 · Cited by 21
A predictive model for acute exacerbation of idiopathic interstitial pneumonias
Karayama, M., Aoshima, Y., Suzuki, T., Mori, K., Yoshizawa, N., Ichikawa, S., Kato, S., Yokomura, K., Kono, M., Hashimoto, D., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01634-2022 · Cited by 18
Self-citationŠtefániková, M., Doubková, M., Ovesná, P., Šterclová, M., Lacina, L., Žůrková, M., Plačková, M., Bartoš, V., Janíčková, I., Bittenglová, R., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02450-3 · Cited by 19
Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition
Calaras, D., Mathioudakis, A. G., Lázár, Z., & Corlăteanu, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061636 · Cited by 17
Behr, J., Nathan, S. D., Costabel, U., Albera, C., Wuyts, W. A., Glassberg, M. K., Haller, H., Alvaro, G., Gilberg, F., Samara, K. D., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02565-3 · Cited by 22
Self-citationDempsey, T. M., Thao, V., Helfinstine, D. A., Chang, Y.-H. H., Sangaralingham, L. R., & LIMPER, A. H. (2023) · European Respiratory Journal · doi:10.1183/13993003.01299-2023 · Cited by 16
Young, O. N., Bourke, J. E., & Widdop, R. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115839 · Cited by 17
Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions
Eriksson, O., & Velikyan, I. (2023) · Pharmaceuticals · doi:10.3390/ph16111540 · Cited by 14
Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6
Höhne, K., Wagenknecht, A., Maier, C., Engelhard, P., Goldmann, T., Schließmann, S. J., Plönes, T., Trepel, M., Eibel, H., Müller–Quernheim, J., et al. (2024) · Cells · doi:10.3390/cells13030238 · Cited by 13
“Currently, two new drugs have been approved for the therapy of mild to moderate fibrosis in IPF; however, although these drugs slow down disease progression, they do not induce a “restitutio ad integrum” [7,8].”
BackgroundInfluentialA narrative review of the role of HDAC6 in idiopathic pulmonary fibrosis
Yu, H., Liu, S., Wang, S., & Gu, X. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1183 · Cited by 16
Mota, P. C., Soares, M. L., Ferreira, A. C., Santos, R. F., Rufo, J. C., Vasconcelos, C. D., Carvalho, A., Guimarães, S., Vasques‐Nóvoa, F., Cardoso, C. G., et al. (2024) · Pulmonology · doi:10.1016/j.pulmoe.2024.01.002 · Cited by 17
Liao, K., & Chen, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1309712 · Cited by 18
Kulkarni, T., Criner, G. J., Kass, D. J., Rosas, I. O., Scholand, M. B., Dilling, D. F., Summer, R. S., & Duncan, S. R. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02957-3 · Cited by 16
Zhang, Q., Li, G., Zhao, G., Yan, C., Lv, H., Fu, Y., Li, Y., & Zhao, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106779 · Cited by 17
Zhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02845-8 · Cited by 19
Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02875-2 · Cited by 16
“Though there are no curative treatment options for IPF, two molecular therapies (nintedanib and pirfenidone) have demonstrated efficacy in reducing disease progression [6, 7] and improving survival [8].”
BackgroundWei, X., Jin, C., Li, D., Wang, Y., Zheng, S., Feng, Q., shi, N., Kong, W., Ma, X., & Wang, J. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.06.008 · Cited by 18
Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review
Thakkar, D., Singh, S., & Wairkar, S. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02869-9 · Cited by 18
Understanding myofibroblast origin in the fibrotic lung
Zabihi, M., Felordi, M. S., Lingampally, A., Bellusci, S., Chu, X., & Agha, E. E. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.003 · Cited by 17
Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
Cruwys, S., Hein, P., Humphries, B., & Black, D. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104207 · Cited by 20
In Vitro Modeling of Idiopathic Pulmonary Fibrosis: Lung-on-a-Chip Systems and Other 3D Cultures
Corona, C., Man, K., Newton, C. A., Nguyen, K. T., & Yang, Y. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111751 · Cited by 13
“In 2014, the Federal Drug Administration (FDA) approved the therapeutics pirfenidone and nintedanib, which have been shown to slow the decline in lung function but do not cure the disease [9,10].”
BackgroundPotential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future
Fiorentù, G., Bernardinello, N., Giulianelli, G., Cocconcelli, E., Balestro, E., & Spagnolo, P. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03129-3 · Cited by 15
Imaging of Idiopathic Pulmonary Fibrosis
Kusmirek, J. E., Martin, M. D., & Kanne, J. P. (2016) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2016.05.004 · Cited by 15
Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs
Holland, A. E. (2015) · Respirology · doi:10.1111/resp.12581 · Cited by 14
Landmark approvals in idiopathic pulmonary fibrosis
Ratner, M. (2014) · Nature Biotechnology · doi:10.1038/nbt1114-1069 · Cited by 14
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
NAIR, G. B., Matela, A., Kurbanov, D., & Raghu, G. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177461 · Cited by 14
Self-citationCotton, C. V., Spencer, L. G., New, R. P., & Cooper, R. G. (2016) · Rheumatology · doi:10.1093/rheumatology/kew320 · Cited by 14
Recent advances in managing idiopathic pulmonary fibrosis
Scelfo, C., Caminati, A., & Harari, S. A. (2017) · F1000Research · doi:10.12688/f1000research.10720.1 · Cited by 15
Health economic evaluation in idiopathic pulmonary fibrosis in France
Fanny, P., Cottin, V., Laura, C., Luciani, L., Lay, K. L., & Bénard, S. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1433143 · Cited by 15
Self-citationTanaka, S., Miyoshi, K., Higo, H., Kurosaki, T., Otani, S., Sugimoto, S., Yamane, M., Kiura, K., Toyooka, S., & Oto, T. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.12.002 · Cited by 15
A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis
Moran‐Mendoza, O., Colman, R., Kalluri, M., Cabalteja, C., & Harle, I. A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1627204 · Cited by 15
Hirano, C., Ohshimo, S., Horimasu, Y., Iwamoto, H., Fujitaka, K., Hamada, H., Kohno, N., Komoto, D., Awai, K., Shime, N., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122069 · Cited by 17
“Recent trials showed that nintedanib can reduce the risk of AE-IPF [33,34].”
BackgroundSelf-citationFibroblast Growth Factor Inhibitors in Lung Fibrosis: Friends or Foes?
Guzy, R. D. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0156ed · Cited by 14
Wang, Z., Qu, S., Zhu, J., Chen, F., & Ma, L. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-2842 · Cited by 16
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors
Iyer, R. V., Konda, B., Fountzilas, C. K., Mukherjee, S., Owen, D. H., Attwood, K. M., Wang, C., Maguire, O., Minderman, H., Suffren, S., et al. (2020) · Cancer · doi:10.1002/cncr.32994 · Cited by 16
Corral, M., Chang, E. Y., Broder, M. S., Gokhale, S., & Reddy, S. R. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0084 · Cited by 14
Senoo, S., Miyahara, N., Taniguchi, A., Oda, N., Itano, J., Higo, H., Hara, N., Watanabe, H., Kano, H., Suwaki, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236935 · Cited by 14
“One of the eligibility criteria for the INPULSIS trials [3] was predicted FVC> 50%, and patients with limited pulmonary function were excluded.”
BackgroundInfluentialBarranco‐Garduño, L. M., Buendía-Roldán, I., Rodriguez, J. J., González‐Ramírez, R., Cervantes-Nevarez, A., Neri-Salvador, J. C., Carrasco‐Portugal, M. D. C., Castañeda‐Hernández, G., Martínez‐Espinosa, K., Selman, M., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05279 · Cited by 17
“There was no effective treatment for IPF until 2014, when pirfenidone and nintedanib were proposed as therapeutic options for this disease [5, 6].”
BackgroundSelf-citationAntifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
Skurikhin, Е. G., Nebolsin, V. E., Widera, D., Ermakova, N. N., Pershina, О. V., Pakhomova, A. V., Krupin, V. A., Pan, E. S., Zhukova, М. А., Novikov, F. N., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218380 · Cited by 14
“In most cases, the prognosis of IPF is unfavorable, with a life expectancy of five years after diagnosis [24,25].”
BackgroundLung organoids and other preclinical models of pulmonary fibrosis
Oglesby, I. K., Schweikert, A., Fox, B., Redmond, C., Donnelly, S. C., & Hurley, K. (2021) · QJM · doi:10.1093/qjmed/hcaa281 · Cited by 15
Schrader, M., Sathananthan, M., & Jeganathan, N. (2021) · Journal of Intensive Care Medicine · doi:10.1177/0885066621989244 · Cited by 14
Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Lettieri, S., Oggionni, T., Lancia, A., Bortolotto, C., & Stella, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062882 · Cited by 16
Management of patients with fibrosing interstitial lung diseases
Morrow, L. E., Hilleman, D. E., & Malesker, M. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab375 · Cited by 15
Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation
Koga, Y., Satoh, T., Kaira, K., Hachisu, Y., Ishii, Y., Yajima, T., Hisada, T., Yokoo, H., & Dobashi, K. (2021) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.1c00659 · Cited by 15
Joerns, E. K., Adams, T. N., Newton, C. A., Bermas, B. L., Karp, D., Batra, K., Torrealba, J., Davila, L., Reisch, J., Glazer, C., et al. (2021) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001808 · Cited by 13
Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention
Yoon, H., & Uh, S. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0053 · Cited by 15
Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population
Chérrez-Ojeda, I., Cortés-Telles, A., Gochicoa‐Rangel, L., Camacho-Leon, G., Mautong, H., Robles‐Velasco, K., & Faytong‐Haro, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091393 · Cited by 16
Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02915-6 · Cited by 15
Interstitial Lung Disease in Mixed Connective Tissue Disease: An Advanced Search
Santacruz, J. C., Mantilla, M. J., Rodríguez-Salas, G., Rueda, I., Pulido, S., Varela, D. C., & Londoño, J. D. (2023) · Cureus · doi:10.7759/cureus.36204 · Cited by 14
“Nintedanib can cause fetal harm so a negative pregnancy test is imperative in women of childbearing potential before starting it, also guaranteeing an effective contraceptive method during the time of treatment [35].”
BackgroundZhang, H., Fang, S., Wang, C., Wang, W., Wu, J., Wang, C., Xu, B., & Zhang, Y. (2015) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0057 · Cited by 14
Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome
Chang, C.-H., Juan, Y. H., Hu, H., Kao, K. C., & Lee, C.-S. (2017) · QJM · doi:10.1093/qjmed/hcx190 · Cited by 12
Novel formononetin-7-sal ester ameliorates pulmonary fibrosis via MEF2c signaling pathway
Zhao, X., Qu, G., Song, C., Li, R., Liu, W., Lv, C., Song, X., Zhang, J., & Li, M. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.07.005 · Cited by 14
Impact of mediastinal lymph node enlargement on the prognosis of idiopathic pulmonary fibrosis
Sin, S., Lee, K. H., Hur, J. H., Lee, S. H., Lee, Y. J., Cho, Y., Yoon, H. I., Lee, J. H., Lee, C. T., & Park, J. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201154 · Cited by 13
Assayag, D., Camp, P. G., Fisher, J. H., Johannson, K. A., Kolb, M. R. J., Lohmann, T., Manganas, H., Morisset, J., Ryerson, C. J., Shapera, S., et al. (2018) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2018.1503456 · Cited by 17
Self-citationNakano, A., Ohkubo, H., Fukumitsu, K., Fukuda, S., Kanemitsu, Y., Takemura, M., Maeno, K., Ito, Y., Oguri, T., & Niimi, A. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1890-18 · Cited by 15
Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review
Lodhi, T., Hughes, G., Stanel, S. C., Chaudhuri, N., & Hayton, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01036-y · Cited by 16
Majewski, S., Szewczyk, K., Białas, A. J., Miłkowska-Dymanowska, J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101590 · Cited by 14
“Both nintedanib and pirfenidone, independently, have been shown to slow the disease progression limiting the decline of lung function in patients with IPF [45,46].”
BackgroundDeng, D., Pei, H., Lan, T., Zhu, J., Tang, M., Xue, L., Yang, Z., Zheng, S., Ye, H., & Chen, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111790 · Cited by 15
Boxhammer, E., Lehle, K., Schmid, Ç., & von Suesskind-Schwendi, M. (2020) · Experimental Lung Research · doi:10.1080/01902148.2020.1738594 · Cited by 17
Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis
Wang, Y., Yella, J., Ghandikota, S. K., Cherukuri, T. C., Ediga, H. H., Madala, S. K., & Jegga, A. G. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620971143 · Cited by 16
“However, drug induced side-effect profiles of these two drugs are formidable and their therapeutic effects are suppressive rather than pulmonary fibrosis remission or reversal (3, 4).”
BackgroundNO‐sensitive guanylyl cyclase in the lung
Friebe, A., & Englert, N. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15345 · Cited by 17
Németh, J., Schundner, A., & Frick, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.611728 · Cited by 17
“To date, Nintedanib and Pirfenidone are the only approved drugs for treatment of IPF (47, 48).”
BackgroundDonno, M. D., Sorbo, A. D., & Micco, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-26664-6_40 · Cited by 15
Chung, J. H., Montner, S. M., Thirkateh, P., Cannon, B., Barnett, S. D., & Nathan, S. D. (2021) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001230 · Cited by 14
Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241232561 · Cited by 15
Luo, C., Huang, C., Zhu, Y., Zhou, Y., Qiao, Y., Shi, C., Gao, Y., Guo, Y., & Wei, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07573-5 · Cited by 22
The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair
Nahm, W. J., & Falanga, V. (2025) · International Wound Journal · doi:10.1111/iwj.70513 · Cited by 17
Ma, M., Chu, Z., Quan, H., Li, H., Zhou, Y., Han, Y., Li, K., Pan, W., Wang, D., Yan, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1524654 · Cited by 22
Kim, C. G., Jang, M., Oh, C., Jeon, O. H., Choi, B. H., Kim, K., Park, J., & Kim, H. K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114005 · Cited by 17
Yu, W., Zhou, H., Goldin, J. G., Wong, W. K., & Kim, G. H. J. (2021) · Medical Physics · doi:10.1002/mp.14754 · Cited by 15
Minimal clinically important difference in idiopathic pulmonary fibrosis
Kang, M., Marts, L. T., Kempker, J. A., & Veeraraghavan, S. (2021) · Breathe · doi:10.1183/20734735.0345-2020 · Cited by 17
BMP1 is not required for lung fibrosis in mice
Ma, H., N’Diaye, E.-N., Caplazi, P., Huang, Z., Arlantico, A., Jeet, S., Wong, A., Brightbill, H. D., Li, Q., Wong, W. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09557-3 · Cited by 14
Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know
Joerns, E. K., Adams, T. N., Sparks, J. A., Newton, C. A., Bermas, B. L., Karp, D. R., & Makris, U. E. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01072-8 · Cited by 14
Park, S., Park, J. Y., Nahm, J. H., Kim, G., Cho, Y. L., Kang, W. J., & Key, J. (2022) · Materials Today Chemistry · doi:10.1016/j.mtchem.2022.101181 · Cited by 13
Li, J., Yu, X., Xie, Y., Yang, S.-G., Zhao, L., Zhou, M., & Meng, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1053356 · Cited by 14
“Although more and more relevant treatment researches have been conducted or being conducted in IPF, only pifenidone and nintedanib obtained evidence-based efficacy and were recommended in the guidelines up to now (King et al., 2014; Richeldi et al., 2014; Raghu et al., 2015; Behr, 2016; Cottin et al., 2017; Behr et al…”
BackgroundShao, G., Hawle, P., Akbari, K., Horner, A., Hintenberger, R., Kaiser, B., Lamprecht, B., & Lang, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1043720 · Cited by 15
“After the advent of the anti-fibrotic drugs Pirfenidone and Nintedanib had fundamentally changed the therapeutic landscape in IPF (6, 7), increasing evidence also suggested their use in systemic sclerosis (SSC)-ILD or progressive fibrosing ILD other than IPF (8–12).”
BackgroundInfluentialZhao, T., Zhou, Z., Zhao, S., Wan, H., Li, H., Hou, J., Wang, J., Qian, M., & Shen, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154919 · Cited by 14
Upperton, S., Beirne, P., Bhartia, B., Boland, A. C., Bradley, C., Crosbie, P. A. J., Darby, M., Eckert, C., Gabe, R., Hancock, N., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001490 · Cited by 13
Shakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02582-4 · Cited by 19
Idiopathic Pulmonary Fibrosis: From Common Microscopy to Single-Cell Biology and Precision Medicine
Selman, M., & Pardo, A. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202309-1573pp · Cited by 14
Self-citationLucà, S., Pagliuca, F., Perrotta, F., Ronchi, A., Mariniello, D. F., Natale, G., Bianco, A., Fiorelli, A., Accardo, M., & Franco, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073618 · Cited by 19
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.